Clinical Trial

A Study of LCAR-AIO CAR-T Cells for Treating Relapsed/Refractory Neurological Autoimmune Diseases

Withdrawn Phase 1
View on ClinicalTrials.gov →
Why the trial stopped
Legend discontinues the development of the IMP.
Summary
This is a prospective, single-arm, open-label, dose-exploration and expansion clinical study of LCAR-AIO in adult subjects with relapsed/refractory neurological autoimmune diseases.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-03-09; most recent amendment 2026-06-21.
Status change: Recruiting → Withdrawn 2026-06-21
Status change: Not Yet Recruiting → Recruiting 2025-06-06
Trial Details
NCT Number NCT06869278
Lead Sponsor Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Collaborators: Nanjing Legend Biotech Co.
Conditions Multiple Sclerosis (MS), Neuromyelitis Optica Spectrum Disease (NMOSD), Anti-Myelin Oligodendrocyte Glycoprotein-IgG Associated Disorders (MOGAD), Myasthenia Gravis
Start Date 2025-06-17
Primary Completion 2025-06-17 (estimated)
Study Completion 2025-06-17 (estimated)
Updated on ClinicalTrials.gov 2026-06-24